Deucravacitinib
Tyrosine Kinase 2 Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: BMS-986165, sotyktu
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Deucravacitinib is an onp drug in the Tyrosine Kinase 2 Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2022. Its mechanism of action is classified as Tyrosine Kinase 2 Inhibitors. DrugCentral lists 8 molecular targets, including TYK2, JAK1 and JAK3. Recorded indications include Erythrodermic psoriasis, Plaque psoriasis and Pustular psoriasis.
- Approval status: onp (first approved 2022 by the FDA).
- Drug class: Tyrosine Kinase 2 Inhibitor.
- Mechanism of action: Tyrosine Kinase 2 Inhibitors.
- Molecular targets: TYK2, JAK1, JAK3 and JAK2 (8 listed in DrugCentral).
- Indications: Erythrodermic psoriasis, Plaque psoriasis and Pustular psoriasis.
- ATC code: L04AF07 (Janus-associated kinase (JAK) inhibitors).
- Molecular formula: C20H22N8O3; molecular weight 425.47 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (3)
- Erythrodermic psoriasis
- Plaque psoriasis
- Pustular psoriasis
Contraindications (2)
- Active tuberculosis
- Severe active infection
Mechanism & targets
| Mechanism of action (MoA) | Tyrosine Kinase 2 Inhibitors |
|---|---|
| Established pharmacologic class | Tyrosine Kinase 2 Inhibitor |
Molecular targets (8)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Non-receptor tyrosine-protein kinase TYK2 | TYK2 | inhibitor | IC50 9.70 |
| Tyrosine-protein kinase JAK1 | JAK1 | inhibitor | IC50 9.00 |
| Tyrosine-protein kinase JAK3 | JAK3 | unknown | IC50 8.52 |
| Tyrosine-protein kinase JAK2 | JAK2 | unknown | Kd 8.00 |
| Signal transducer and activator of transcription 1-alpha/beta | STAT1 | unknown | IC50 7.47 |
| Signal transducer and activator of transcription 3 | STAT3 | unknown | IC50 7.05 |
| Non-receptor tyrosine-protein kinase TYK2 | Tyk2 | unknown | IC50 7.00 |
| Bone morphogenetic protein receptor type-2 | BMPR2 | inhibitor | IC50 6.71 |
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2023-03-24 | EMA | — | BRISTOL-MYERS SQUIBB PHARMA EEIG | |
| 2022-09-26 | PMDA | — | BRISTOL-MYERS SQUIBB K.K. | |
| 2022-09-09 | FDA | — | BRISTOL-MYERS SQUIBB |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L04AF07 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Janus-associated kinase (JAK) inhibitors |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Acne | 613.6 |
| Skin burning sensation | 291.3 |
| Pruritus | 272.3 |
| Erythema | 264.0 |
| Mouth ulceration | 182.2 |
| Rash | 114.2 |
| Folliculitis | 97.0 |
| Burning sensation | 75.0 |
| Adverse event | 68.0 |
| Therapy interrupted | 55.4 |
| Drug ineffective | 43.1 |
| Acne cystic | 42.8 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Deucravacitinib is on its molecule page.
| Molecular formula | C20H22N8O3 |
|---|---|
| Molecular weight | 425.47 g/mol |
| CAS number | 1609392-27-9 |
| InChIKey | BZZKEPGENYLQSC-FIBGUPNXSA-N |
| PubChem CID | 134821691 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Deucravacitinib used for?
DrugCentral lists the following indications for Deucravacitinib: Erythrodermic psoriasis, Plaque psoriasis and Pustular psoriasis.
How does Deucravacitinib work?
Deucravacitinib is classified as Tyrosine Kinase 2 Inhibitors; its molecular targets in DrugCentral include TYK2 (inhibitor), JAK1 (inhibitor), JAK3 and JAK2.
When was Deucravacitinib first approved?
Deucravacitinib was first approved by the FDA in 2022.
What drug class does Deucravacitinib belong to?
Deucravacitinib is in the Tyrosine Kinase 2 Inhibitor class.
What is the chemical formula of Deucravacitinib?
Deucravacitinib has the molecular formula C20H22N8O3 and a molecular weight of 425.47 g/mol.
Browse: all drugs starting with D · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5677 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL4435170 — compound record and bioactivity
- PubChem CID 134821691 — chemical identifiers
- DrugBank DB16650 — drug record
- FDA UNII N0A21N6RAU — substance identity
- DailyMed: FDA labels for Deucravacitinib — current prescribing information (label search)
- UniProt P29597 (TYK2) — target protein
- UniProt P23458 (JAK1) — target protein
- UniProt P52333 (JAK3) — target protein
- UniProt O60674 (JAK2) — target protein
- UniProt P42224 (STAT1) — target protein
- UniProt P40763 (STAT3) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.